{"certainAgreement":{"otherDetails":"The investigator agrees not to publish or publicly present any interim results\n\nof the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor, 45 days prior to submission, review copies of abstracts or manuscripts for publication that report any results of the study. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission, for the purpose of making good faith efforts to discuss/resolve any such issues.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Due to low response rate for colorectal cancer in interim analyses, low enrollment in head \\& neck and non-small cell lung cancer groups due to low methylation rates, and low overall response rate in esophageal cancer group, the study was terminated."},"pointOfContact":{"email":"ClinicalTrialsDisclosure@merck.com","organization":"Merck Sharp & Dohme Corp.","title":"Senior Vice President, Global Clinical Development"}}